Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 19, 2022
- Pharmaceuticals
- R&D
CHMP Recommends Expansion of EU Label for Hemlibra to Include People with Moderate Hemophilia A
TOKYO, December 19, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on the anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute Hemlibra® [generic name: emicizumab (genetical recombination)]. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve the additional indication of Hemlibra for moderate hemophilia A.
Please refer to the link below for details:
-
CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
https://www.roche.com/media/releases/med-cor-2022-12-16
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp